title: The evolution of systemic therapy in sarcoma.
abstract: Approximately 50% of patients with localized soft tissue sarcomas will develop recurrent disease after complete surgical resection, requiring alternative means of treatment. Conventional chemotherapy comprising of doxorubicin and ifosfamide has shown benefit in advanced disease, however, there remains a clear need for more effective, less toxic, therapies for the treatment of this heterogeneous group of mesenchymal malignancies. Recently, greater emphasis has been placed on the underlying biology of individual sarcoma subtypes, with the development and evaluation of novel therapies both in common and in rare subtypes. In addition, there is a greater specificity in the selection of chemotherapy agents based on activity in individual histological subtypes. Despite these advances the management of sarcoma, and in particular of rare subtypes, remains a major challenge. Some histological subtypes are resistant to conventional chemotherapy and patients with these diseases should be offered participation in early phase clinical trials of novel drugs.
authors: The Royal Marsden Hospital, London, UK.
authors: Anastasia
authors: A
authors: Constantinidou
authors: Seth
authors: S
authors: Pollack
authors: Elizabeth
authors: E
authors: Loggers
authors: Eve
authors: E
authors: Rodler
authors: Robin L
authors: RL
authors: Jones
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002817:Chordoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018223:Dermatofibrosarcoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D004149:Dioxoles / Q000627:therapeutic use; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D061988:Proteasome Inhibitors / Q000627:therapeutic use; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors; D012509:Sarcoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000473:pathology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D043823:Taxoids / Q000627:therapeutic use; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use; D000077606:Trabectedin; D000093542:Gemcitabine
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004149:Dioxoles; D061988:Proteasome Inhibitors; D043823:Taxoids; D044005:Tetrahydroisoquinolines; D003841:Deoxycytidine; D000077143:Docetaxel; C546842:MTOR protein, human; D017526:Receptor, IGF Type 1; D058570:TOR Serine-Threonine Kinases; D000077606:Trabectedin; D000093542:Gemcitabine